Effect of antimicrobial therapy on progression free survival of immunotherapy and chemo-/ immunotherapy in patients with NSCLC.

被引：0
|
作者：
Uhlenbruch, M. [1 ]
Krueger, S. [1 ]
机构：
[1] Florence Nightingale Krankenhaus Dusseldorf, Klin Pneumol Kardiol Internist Intensivmed, Dusseldorf, Germany
来源：
PNEUMOLOGIE | 2024年 / 78卷
关键词：
D O I：
10.1055/s-0044-1778946
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
FV 27
引用
收藏
页码：S97 / S98
页数：2
相关论文
共 50 条
  • [21] Clinical outcomes in COVID-19 patients with cancer who are treated with chemo- or immunotherapy.
    Hatic, Haris
    Jung, Jenny B.
    Hearld, Kristine Ria
    Deshane, Jessy
    Das, Devika Govind
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E18699 - E18699
  • [22] Survival of Patients with advanced NSCLC on Immunotherapy based on Cytokine Profile in Serum
    Schindler, H.
    Lusky, F.
    Elshiaty, M.
    Bozorgmehr, F.
    Kuon, J.
    Shah, R.
    Schneider, M.
    Eichhorn, F.
    Angeles, A.
    Janke, F.
    Kriegsmann, M.
    Kazdal, D.
    Kirchner, M.
    Stenzinger, A.
    Sultmann, H.
    Thomas, M.
    Christopoulos, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 97 - 97
  • [23] A Case Report of Sustained Survival of NSCLC Treated with Combination of Cell Therapy and Immunotherapy
    De Guzman, M. S.
    Heralde, F., III
    Barzaga, M. T.
    Bilbao, A.
    Tan-Liu, N.
    Apelado, M. P.
    Panuelos, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S682 - S682
  • [24] Stromal PDGFR-β Expression Influences Postoperative Survival of NSCLC Patients Receiving Preoperative Chemo- or Chemo-Radiotherapy
    Kanzaki, R.
    Naito, H.
    Eino, D.
    Kawamura, T.
    Ose, N.
    Funaki, S.
    Shintani, Y.
    Minami, M.
    Okumura, M.
    Takakura, N.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2361 - S2362
  • [25] Removal of TNF-Rs frees TNF-a's anticancer activity alone or in combination chemo- or immunotherapy in advanced NSCLC
    Bozkurt, M.
    Gokhan, D.
    Teomete, M.
    Turam, C.
    Florin, L.
    Ostrowski, A.
    Segal, R.
    Manax, V.
    ANNALS OF ONCOLOGY, 2023, 34
  • [26] INTRACRANIAL PROGRESSION IS LESS COMMON IN PATIENTS WITH ADVANCED NSCLC RECEIVING CANCER IMMUNOTHERAPY
    Kemmotsu, Naoya
    Ninomiya, Kiichiro
    Otani, Yoshihiro
    Michiue, Hiroyuki
    Tanaka, Shota
    Togashi, Yosuke
    NEURO-ONCOLOGY, 2024, 26
  • [27] Effect and Tolerability of Immunotherapy in Patients with NSCLC with or without Brain Metastasis
    Bjornhart, Birgitte
    Hansen, Karin Holmskov
    Asmussen, Jon Thor
    Jorgensen, Trine Lembrecht
    Herrstedt, Jorn
    Schytte, Tine
    CANCERS, 2022, 14 (07)
  • [28] Radiotherapy for oligoprogression in metastatic non-small cell lung cancer patients receiving (chemo-)immunotherapy
    Deng, M.
    Bozorgmehr, F.
    Weykamp, F.
    Lang, K.
    Regnery, S.
    Held, T.
    Weusthof, K.
    Bauer, L.
    Waldsperger, H.
    Shafie, R. E.
    Rieken, S.
    Christopoulos, P.
    Thomas, M.
    Debus, J. Peter
    Adeberg, S.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2022, 198 (SUPPL 1) : S105 - S105
  • [29] Adherence to Treatment Protocol of Patients Submitted to Neoadjuvant (Chemo) Immunotherapy in Resectable NSCLC: Ameta Analysis
    Guerrera, F.
    Gallina, F. T.
    Balzani, E.
    Marinelli, D.
    Nuccio, A.
    Ferrara, R.
    Di Federico, A.
    Ambrosi, F.
    Faccioli, E.
    Mammana, M.
    Ferro, A.
    Sepulcri, M.
    Giusti, R.
    Pittaro, A.
    Viscardi, G.
    Bertoglio, P.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S56 - S57
  • [30] Evaluation of Local Therapy for Oligoprogressive Disease in Metastatic NSCLC Patients on Immunotherapy
    Giustini, N.
    Patel, S.
    Gold, K.
    Mitchell, W.
    Husain, H.
    Bazhenova, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S358 - S359
12345